Cargando…

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

BACKGROUND: New anti-tuberculosis regimens that are shorter, simpler, and less toxic than those that are currently available are needed as part of the global effort to address the tuberculosis epidemic. We aimed to investigate the bactericidal activity and safety profile of combinations of bedaquili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tweed, Conor D, Dawson, Rodney, Burger, Divan A, Conradie, Almari, Crook, Angela M, Mendel, Carl M, Conradie, Francesca, Diacon, Andreas H, Ntinginya, Nyanda E, Everitt, Daniel E, Haraka, Frederick, Li, Mengchun, van Niekerk, Christo H, Okwera, Alphonse, Rassool, Mohammed S, Reither, Klaus, Sebe, Modulakgotla A, Staples, Suzanne, Variava, Ebrahim, Spigelman, Melvin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641992/ https://www.ncbi.nlm.nih.gov/pubmed/31732485 http://dx.doi.org/10.1016/S2213-2600(19)30366-2

Ejemplares similares

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
por: Oelofse, S., et al.
Publicado: (2021)

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
por: Tweed, C. D., et al.
Publicado: (2021)

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
por: Gomez, Gabriela Beatriz, et al.
Publicado: (2021)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
por: Li, Si-Yang, et al.
Publicado: (2017)

An Exposure-Response Perspective on the Clinical Dose of Pretomanid
por: Nedelman, Jerry R., et al.
Publicado: (2020)

Male reproductive hormones in patients treated with pretomanid
por: Boekelheide, K., et al.
Publicado: (2022)

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid
por: Timm, Juliano, et al.
Publicado: (2023)

1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project
por: Goswami, Neela, et al.
Publicado: (2021)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis
por: Li, Hanbin, et al.
Publicado: (2019)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers
por: Li, Mengchun, et al.
Publicado: (2020)

Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling
por: Mehta, Krina, et al.
Publicado: (2023)

Daily Dosing for Bedaquiline in Patients with Tuberculosis
por: Salinger, David H., et al.
Publicado: (2019)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys
por: Bruning-Barry, Rebecca, et al.
Publicado: (2022)

Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 System
por: Demers, Anne-Marie, et al.
Publicado: (2016)

Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Pretomanid for tuberculosis treatment: an update for clinical purposes
por: Occhineri, Sara, et al.
Publicado: (2022)

Maturation and Mip-1β Production of Cytomegalovirus-Specific T Cell Responses in Tanzanian Children, Adolescents and Adults: Impact by HIV and Mycobacterium tuberculosis Co-Infections
por: Portevin, Damien, et al.
Publicado: (2015)

Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice
por: Irwin, Scott M., et al.
Publicado: (2016)

Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania
por: Juma, Saumu Pazia, et al.
Publicado: (2019)

Optimization of SABRE for polarization of the tuberculosis drugs pyrazinamide and isoniazid
por: Zeng, Haifeng, et al.
Publicado: (2013)

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis
por: Dierig, A, et al.
Publicado: (2023)

Pyrazinamide induced thrombocytopenia
por: Kant, Surya, et al.
Publicado: (2010)

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis
por: Berry, Catherine, et al.
Publicado: (2022)

Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children
por: Svensson, Elin M., et al.
Publicado: (2018)

Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date
por: Stancil, Stephani L, et al.
Publicado: (2021)

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
por: Bateson, Anna, et al.
Publicado: (2022)

Short and Efficient Synthesis of the Antituberculosis Agent Pretomanid from (R)-Glycidol
por: Lucas, Tobias, et al.
Publicado: (2023)

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
por: Diacon, Andreas H., et al.
Publicado: (2020)

Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro
por: Hu, Minghao, et al.
Publicado: (2020)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Electrochemical data of Co(II) complexes containing phenanthroline functionalized ligands
por: Ferreira, Hendrik, et al.
Publicado: (2018)

Cyclic voltammetry data of polypyridine ligands and Co(II)-polypyridine complexes
por: Ferreira, Hendrik, et al.
Publicado: (2018)

Kinetic Study of the Oxidative Addition Reaction between Methyl Iodide and [Rh(imino-β-diketonato)(CO)(PPh)(3)] Complexes, Utilizing UV–Vis, IR Spectrophotometry, NMR Spectroscopy and DFT Calculations
por: Ferreira, Hendrik, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_prbme315htaff25gehdkr3h5pp